Alterity Therapeutics Share Price and Company Fundamentals
Last traded: Today at 5:13 AM
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
|Primary activities||The Company's business is the development of therapeutic drugs for age-related diseases.|
|Industry / Sector||Biotechnology / Healthcare|
|Full time employees||12|
|Mailing address||460 Bourke Street Level 3 Melbourne VIC 3000 Australia|
|Phone / Fax||61 3 9349 4906 /|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Alterity Therapeutics does not pay dividends.
As of May 2021, following are the company executives and directors listed on Alterity Therapeutics.
|Mr. Geoffrey Paul Kempler B.Sc., B.Sc||Co-Founder & Non-Exec. Chairman||65||446.01k|
|Dr. David A. Stamler||CEO, Chief Medical Officer & Sr. VP of Clinical Devel.||59||625.47k|
|Ms. Kathryn J. E. Andrews||Chief Financial Officer||53||257.86k|
|Dr. Rudolph Emile Tanzi||Chief Scientific Advisor and Member of R&D Advisory Board|
|Dr. Steven D. Targum||Chief Medical Advisor|
|Dr. Robert Cherny||Head of Research|
|Mr. Phillip Allen Hains||Company Sec.||61|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Alterity Therapeutics is 54.18M and its enterprise value is 25.9M. The enterprise value to revenue ratio of ATH is 919.81.
The ATH's stocks Beta value is 1.04 making it 4% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Alterity Therapeutics (ATH)
Alterity Therapeutics (ASX:ATH) Frequently Asked Questions
1. What is Alterity Therapeutics's Stock Symbol?
Alterity Therapeutics trades on ASX under the ticker symbol "ATH".
2. What is Alterity Therapeutics's stock price today?
One share of ATH stock can currently be purchased for approximately $0.026.
3. How can I contact Alterity Therapeutics?
Alterity Therapeutics's mailing address is 460 Bourke Street Level 3 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9349 4906.
4. What is Alterity Therapeutics's official website?
The official website of Alterity Therapeutics is http://www.alteritytherapeutics.com.
5. Which share registry manages Alterity Therapeutics's stock?
Alterity Therapeutics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.